INSUBCONTINENT EXCLUSIVE:
been underperforming due to a host of issues ranging from regulatory to changing dynamics in the US market.
Thanks to a subdued performance
in the second quarter, the stock has been one of the underperformers in the pharmaceutical sector
entities associated with the promoter group, and other alleged lapses of governance in the operations of the business.
Though the company
responded that it is in compliance with all the applicable legal and regulatory provisions, the response may not be sufficient to allay the
extra sensitive as well as unrelenting towards any lapse of governance, past or present, on the part of the management.
From a pure
defensive stock, Sun Pharma has steadily become a high risk-high return proposition to invest in
price of Rs 1,200 reached in 2015
